D. Boral Capital Reaffirms Buy Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reissued by D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $18.00 price target on the stock.

Several other equities research analysts have also commented on GOVX. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research note on Friday, November 15th. Alliance Global Partners started coverage on GeoVax Labs in a research report on Monday, November 11th. They issued a “buy” rating and a $15.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX opened at $2.25 on Thursday. The stock has a 50 day moving average price of $2.46 and a 200-day moving average price of $2.81. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.38. The firm had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same period in the prior year, the business posted ($4.80) EPS. On average, equities analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.